Sort by: Title  Date

• Alliance in the News, Alliance Views, Video
  Dan Perry on BioCentury This Week: Alzheimer's Research
  
  March 18, 2012
  Related topics: Alzheimer's Disease  Drug Development  Federal Funding  Policy  Research  
  
  
  In a March 18th interview with BioCentury This Week, Alliance for Aging Research President & CEO Daniel Perry shares his thoughts on U.S. funding of Alzheimer’s research. Perry also calls for the U.S. Food and Drug Administration to adopt biomarkers and other tools to detect and treat Alzheimer's disease earlier.
• Alliance in the News, Science in the Spotlight
  Alzheimer’s Biomarkers are Ready for Research
  
  March 7, 2012
  Related topics: Aging Research  Alzheimer's Disease  Brain Health  Drug Development  Drug Safety  Health  Medical Innovation  Policy  Research  
  
  
  In a March 1^st interview, Dr. John Morris, co-chair of the Alzheimer's Disease Biomarker Expert Working Group (convened by the Alliance for Aging Research), explains what biomarkers are and how they will help research in the field of Alzheimer's disease and related dementia.
  
  John C. Morris is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University. He also is the Director and Principal Investigator of the Alzheimer's Disease Research Center.
  
  For More info on the promise of biomarkers in Alzheimer's, click here.
• Brochure
  Taking a Closer Look at Age-Related Macular Degeneration
  
  November 2011 | Alliance for Aging Research
  Related topics: Health  Vision Loss  
  
  
  This popular brochure has been updated to reflect the latest advances in detection, prevention, and treatment (released in November 2011). It guides readers through the latest information on age-related macular degeneration symptoms and risk factors, while offering ways to help reduce risk. The widely used Amsler Grid can still be found on the back cover.
• Document, Testimony
  Alliance President Makes Remarks at a Hearing on Prescription Drug User Fee Act Reauthorization
  
  November 2011
  Related topics: Drug Development  Federal Funding  Policy  
  
  

  On October 24th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public. The PDUFA reauthorization process has historically been conducted through negotiations between the Agency and regulated industries, however the current round of negotiations allowed for patient groups to engage in monthly consultations with FDA representatives to enable all stakeholders to have an early voice in shaping the PDUFA V agreement.

• Document, Fact Sheet
  Detecting Glaucoma: Assessing Your Eye Health with a Comprhensive Eye Exam
  
  October 17, 2011
  Related topics: Health  Prevention  Vision Loss  
  
  
  This tip sheet tells you what to expect during a comprehensive eye exam--the key to detecting glaucoma and preventing its serious consequences.